Communiqués Kobayashi Pharmaceutical Co., Ltd. Deutsche Boerse AG

Actions

KOY

JP3301100008

Produits cosmétiques

Temps réel estimé Tradegate Autres places de cotation 08:33:22 07/07/2026			Varia. 5j.	Varia. 1 janv.
30,90 ^EUR	+5,10%		+5,63%	+4,90%

13/05	Oasis Management sollicite les actionnaires de Kobayashi Pharmaceutical, selon un avis financier	RE
17/04	KOBAYASHI PHARMACEUTICAL CO., LTD. : Jefferies & Co. maintient sa recommandation neutre	ZM

Communiqués

08/05	Kobayashi Pharmaceutical : FY2026（January 1, 2026 - December 31, 2026）1Q Financial Statement Summary	PU
08/05	Kobayashi Pharmaceutical : Financial Overview for First Quarter of Fiscal 2026(Fiscal Year Ending December 31, 2026)	PU
06/03	Oasis Urges Shareholders to Oppose Kobayashi Pharma’s Transition to a Company with an Audit and Supervisory Committee at AGM (Securities Code: 4967 JT)	BU
21/01	Oasis Submits Shareholder Proposals to Kobayashi Pharmaceutical for 2026 AGM	BU
11/11	Kobayashi Pharmaceutical : Financial Overview for Third Quarter of Fiscal 2025(Fiscal Year Ending December 31, 2025)	PU
14/10/25	Court Proceedings Begin in Oasiss Shareholder Derivative Lawsuit Seeking Director Accountability for Kobayashi Pharmaceutical Beni Koji Supplement Tragedy	AQ
14/10/25	Court Proceedings Begin in Oasis’s Shareholder Derivative Lawsuit Seeking Director Accountability for Kobayashi Pharmaceutical Beni-Koji Supplement Tragedy	BU
12/06/25	Voting Cards Reveal that Over 50% of Shareholders Excluding the Founding Family and Related Parties Voted For Oasis’s EGM Proposals and Against Mr. Akihiro Kobayashi’s Renomination at the AGM	BU
09/05/25	Kobayashi Pharmaceutical : FY2025（January 1, 2025 - December 31, 2025）1Q Financial Statement	PU
09/05/25	Kobayashi Pharmaceutical : Financial Overview for First Quarter of Fiscal 2025(Fiscal Year Ending December 31, 2025)	PU
07/04/25	Oasis Files Shareholder Derivative Lawsuit Against Kobayashi Pharmaceutical Directors	BU
11/03/25	Oasis Urges All Shareholders to Vote AGAINST the Appointment of Mr. Akihiro Kobayashi, Mr. Katae, Mr. Ohta and Mr. Takahashi as Directors at the Kobayashi Pharma AGM	BU
17/02/25	Oasis Secures Proxy Advisors' Support for Proposals that Address Serious Governance Concerns at Upcoming Kobayashi Pharma EGM	BU
10/02/25	Kobayashi Pharmaceutical : FY2024（January 1, 2024 - December 31, 2024）Full Year Financial Statement	PU
10/02/25	Kobayashi Pharmaceutical : Financial Overview for Fiscal 2024(Fiscal Year Ended December 31, 2024)	PU
28/01/25	Oasis Initiates Shareholder Derivative Lawsuit Against Kobayashi Pharmaceutical Directors (Securities Code: 4967 JT)	BU
05/12/24	Oasis Calls for EGM at Kobayashi Pharmaceutical to Elect New Outside Directors and Independent Investigator	BU
08/11/24	Kobayashi Pharmaceutical : FY2024（January 1, 2024 - December 31, 2024）3Q Financial Statement	PU
08/11/24	Kobayashi Pharmaceutical : Financial Overview for Third Quarter of Fiscal 2024(Fiscal Year Ending December 31, 2024)	PU
28/09/24	Class action filed against Kobayashi Pharma in Taiwan: reports	AQ
08/08/24	Kobayashi Pharma to exit red yeast rice business amid health scandal	AQ
08/08/24	Kobayashi Pharmaceutical : FY2024（January 1, 2024 - December 31, 2024）2Q Financial Statement	PU
08/08/24	Kobayashi Pharmaceutical : Financial Overview for Second Quarter of Fiscal 2024(Fiscal Year Ending December 31, 2024)	PU
23/07/24	UPDATE1: Kobayashi Pharma chairman, president resign over supplements scandal	AQ
23/07/24	Head of disgraced Japanese pharma company resigns	AQ